Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   - « May » « 2025 » M T W T F S S 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Notsumata, Kazuo
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)	Completed	3	238	Europe, Canada, Japan, US, RoW	Linerixibat, Placebo	GlaxoSmithKline	Pruritus	10/24	12/24
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	08/27	08/27
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH	Active, not recruiting	2	284	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease	01/26	05/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Notsumata, Kazuo
NCT04950127 / 2021-000007-21: Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)	Completed	3	238	Europe, Canada, Japan, US, RoW	Linerixibat, Placebo	GlaxoSmithKline	Pruritus	10/24	12/24
B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B	Active, not recruiting	3	871	Europe, Canada, Japan, US, RoW	Bepirovirsen, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Chronic Hepatitis B, Hepatitis B, Chronic	11/25	05/26
LLSAT, NCT04167358 / 2019-003158-10: Linerixibat Long-term Safety, and Tolerability Study	Active, not recruiting	3	245	Europe, Canada, Japan, US, RoW	Linerixibat	GlaxoSmithKline, GlaxoSmithKline LLC, GlaxoSmithKline Research & Development Limited	Cholestasis	08/27	08/27
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH	Active, not recruiting	2	284	Europe, Canada, Japan, US, RoW	GSK4532990, Placebo	GlaxoSmithKline, GlaxoSmithKline Research & Development Limited	Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease	01/26	05/26